Fibroheal Woundcare Pvt ltd, a leader and pioneer in by products utilisation of SILK and first company from India to have commercialised Silk proteins based medical devices in wound management space has raised 6.3 Cr funding from the promoters and a set of new investors including some leading surgeons, medical professionals and bankers. Fibroheal also have a commitment of another 10 Cr from existing and some new investors.
Fibroheal intends to scale up its go to market, recruit more people, invest in their future robust pipeline of products in medical devices area and create an impact through the economic multiplier potential of Silk and few other biomaterials. Fibroheal with its unique range of products have been healing different types of acute, chronic, traumatic, post operative, non healing or difficult to heal wounds like diabetic ulcers, bed sores, infected C section wounds, accidental trauma etc.
The company has a comprehensive range of products including Foams, mesh, powder, particles, adhesive dressings, sprays, gels etc which are already commercialised and are doing well in the market catering to different types and stages of wounds. Currently more than 500 hospitals are using their range of products with presence across 19+ states. Fibroheal also have a strong e-commerce presence on various digital platforms. As a strong R&D driven organisation, they have 20+ academic collaborations with leading institutes across the world and 6+ industrial collaborations with leading names in area of research.
Fibroheal Woundcare Pvt ltd was started on 06th April 2017 by Vivek Mishra & Bharat Tandon later joined by Mr S Subramanian in 2018 as a co-promoter with trio coming together with an aspiration to create research driven comprehensive wound management and tissue reconstruction company catering to different types and stages of wounds using various new age biomaterials including silk.
Fibroheal has 8+ granted patents in hand and few more in process. As a R&D driven startup, Fibroheal collaborated with IISc, Bangalore and supported a student under PMRF program which led to a joint research translation and commercialisation of an external haemostatic product named “Fibroplug” which is a big success and have treated more than 3000 bleeding cases within 4 months of it’s early introduction cum commercialisation. This joint research collaboration highlights the commitment of Fibroheal towards translational research by actively engaging with various leading science institutes across the world and bridging the gap of industry-academia connect.
About this successful funding round closure, one of the earliest believers of Silk and co-founder of Fibroheal Mr Bharat Tandon who led the round said that:- “Congratulations Vivek and whole team of Fibroheal on successful closure of your Pre Series A Fundraise. As earliest backer of Fibroheal which is pioneer in medical application of Silk Proteins, I am happy to have lead this round because I believe the product pipeline which the R&D team is working on is robust and extremely valuable with great potential, Good luck to the entire team”.
